Trial Profile
A study evaluating safety of roflumilast in the real world.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 12 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society